A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
View MoreAge
18 Years - 65 Years
Sex
All
Healthy Volunteers
Accepts Healthy Volunteers
Medical Condition
Chronic Hepatitis B
Gender
N/A
Date
April 2023 - January 2025
Study Type
Interventional
Study Phase
Phase 1
Product
GS-2829, GS-6779, Placebo for GS-2829, Placebo for GS-6779
Auckland, New Zealand, 1010
Chiayi City, Taiwan, 60002
Chiayi City, Taiwan, 600
Kaohsiung City, Taiwan, 82445
Kaohsiung City, Taiwan, 833
Kaohsiung, Taiwan, 807
Tainan City, Taiwan, 7428
Taipei City, Taiwan, 100229
Taoyuan City, Taiwan, 33305
Share Trial